Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Microsite

Educational site about osteoporosis from Amgen. The site has substantial quantities of patient education materials:
- Information about Osteoporosis
- Know my bones program – which sends new information directly to people once enrolled.
- Talk to your doctor – which is a printable list of questions to bring to their healthcare professional
- Quiz to test people’s knowledge about osteoporosis
- FAQ
- etc…

Visit Know my bones.

Brand name: Know my bones

Generic name/category: Patient education website
Company: Amgen
Country/Market: USA, North America
Indication(s)/use: Osteoporosis
Target: Consumers (DTC)
Tagline: Know my bones
Medium: Internet
Size/duration: Microsite
Publication/Aired: 2009

Ads for osteoporosis treatments on AdPharm

More ads from Amgen

Click on thumbnail to view the full-size ad on AdPharm

I’m ready

I’m ready to take on chemo. And then, take on my next canvas.

Brand name: Neulasta
Generic name/category: Pegfilgrastim, Immunostimulants
Company: Amgen
Country/Market: USA, North America
Indication(s)/use: Reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells
Target: Consumers (DTC)
Tagline: I’m ready
Medium: Print ad
Size/duration: single-page
Publication/Aired: US News & World Report – June 2007

To see all of this brand’s ads on AdPharm, click here

The time is right for innovative research in osteoporosis

Research pinpoints Rank ligand as a key player in bone loss.

RANKL (Receptor Activator for Nuclear Factor ?? B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a molecule important in bone metabolism. This natural and necessary surface-bound molecule activates osteoclasts, cells involved in bone resorption. Overproduction of RANKL is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and psoriatic arthritis.

More on Wikipedia

Generic name/category: Rank ligand, TNF-related
Company: Amgen
Country/Market: Canada, North America
Indication(s)/use: osteoporosis
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: CMAJ – September 1, 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads

For adults with chronic moderate to severe plaque psoriasis
Clearer skin in 3 months

Before Enbrel. An example of one skin area. After Enbrel. Your results may vary.
Example of approximately 75% skin clearance.

If you and your doctor decide that Enbrel is right for you, ask about the Enbrel support co-pay program.
No co-pay for 6 months for eligible patients.

Ask your dermatologist if Enbrel is right for you. Learn more: visit enbrel.com or call 1-888-4ENBREL.

Brand name: Enbrel
Generic name/category: Etanercept, TNF inhibitor
Company: Amgen and Wyeth
Country/Market: USA, North America
Indication(s)/use: Moderate to severe chronic plaque psoriasis (PsA)
Target: Consumers (DTC)
Publication: People Magazine June 15 2009

To see all of this brand’s ads, click here